HomeNewsBusinessCompaniesCOVID-19 impact | Swanky IT campuses may not lose value despite work from home buzz

COVID-19 impact | Swanky IT campuses may not lose value despite work from home buzz

In the long run, lack of work-life balance, mental health issues and poor infrastructure will see techies returning to office.

May 21, 2020 / 19:48 IST
Story continues below Advertisement

Infosys Global Education Centre in Mysuru, dubbed heaven on earth by its trainees, is spread across 337 acres of land with the build area of 12 million sq ft. The total investment in the centre was close to Rs 2,055 crore.

The centre, which is usually buzzing with trainees, is empty since they have been sent home due to the COVID-19 outbreak. The training is now virtual. It is unclear if it would become a permanent feature.

Story continues below Advertisement

The story is more or less the same for other IT firms such as TCS, Wipro or HCL Tech, where majority of the employees continue working from home (WFH).

In the post-COVID-19 era, it makes one wonder, if the campuses will be relevant, especially when remote working and training is becoming a norm.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show